Skip to main content

Table 1 Univariate and multivariate analysis of risk factors for bRFS and DMFS

From: Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy

  Risk factor Reference category Univariate analysis Multivariate analysis
    HR 95% CI p HR 95% CI p
bRFS
  T-stage T3b-T4    0.047    0.112
T1b-T2a   0.64 0.43–0.94 0.025 0.653 0.44–0.98 0.038
T2b-T2c   0.60 0.39–0.91 0.016 0.672 0.43–1.04 0.075
T3a   0.76 0.53–1.09 0.134 0.91 0.63–1.30 0.608
PSA   1.01 1.01–1.02 <.0005 1.015 1.01–1.02 <0.0005
Gleason score GS > 7    0.148    <0.0005
< 7   0.68 0.46–1.00 0.053 0.349 0.23–0.53 <0.0005
= 7   0.83 0.58–1.19 0.307 0.604 0.41–0.89 0.010
ADT duration (continuous)   0.97 0.96–0.99 0.001 0.979 0.96–1.00 0.017
Radiation dose   0.83 0.77–0.89 <0.0005 0.859 0.79–0.93 <0.0005
DMFS
  T-stage T3b-T4    0.204    0.272
T1b-T2a   0.62 0.37–1.02 0.061 0.634 0.38–1.06 0.081
T2b-T2c   0.65 0.38–1.11 0.117 0.695 0.40–1.22 0.204
T3a   0.84 0.54–1.29 0.424 0.916 0.59–1.42 0.694
PSA   1.01 1.00–1.02 0.004 1.009 1.00–1.01 0.011
Gleason score GS > 7    0.137    0.013
< 7   0.61 0.37–0.99 0.047 0.482 0.29–0.79 0.004
= 7   0.77 0.49–1.21 0.254 0.730 0.46–1.17 0.189
ADT duration (continuous)   0.99 0.97–1.01 0.366    
Radiation dose   0.86 0.78–0.95 0.004 0.853 0.77–0.95 0.003
  1. Abbreviations: bRFS biochemical relapse-free survival, CI confidence interval, DMFS distant metastases-free survival